
Privosegtor shows neuroprotective effects in Phase 2 trial for optic neuritis, reducing nerve damage markers.
Oculis Holding AG announced that Privosegtor, in a Phase 2 ACUITY trial, reduced increases in blood biomarkers linked to nerve damage (NfL and GFAP) in patients with optic neuritis compared to placebo. These biomarker improvements support earlier fin...





